Endoscopic treatment versus surgical treatment for T1b esophageal cancer: a systematic review and meta-analysis
A partir d'une revue systématique de la littérature publiée jusqu'en décembre 2023 (9 études, 1 637 patients), cette méta-analyse évalue l'efficacité, du point de vue de la survie globale, et la sécurité d'un traitement endoscopique par rapport à une oesophagectomie pour un cancer de l'oesophage de stade T1b
Background: Endoscopic and surgical treatment are the two most common treatment strategies for resectable esophageal cancer (EC), but the optimal treatment for T1b EC remains controversial. This study aimed to compare the efficacy and safety of endoscopic treatment versus esophagectomy for T1b EC.
Methods: Web of Science, MEDLINE, Scopus, and EMBASE were searched from their inception to December 2023. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines, we used the fixed- and random-effect models for this meta-analysis by RevMan. The primary outcomes included overall survival (OS), recurrence, lymph node metastasis, complete resection rate and positive resection margin. The secondary outcomes were 1-year survival, 3-year survival, 5-year survival, overall mortality rate, EC-specific mortality rate and lymphovascular invasion.
Results: Nine studies with a population of 1,637 patients (endoscopic treatment: 715 patients; surgical treatment: 922 patients) were included. The pooled results showed that surgical treatment was associated with a significantly better OS than endoscopic treatment (Hazard Ratio [HR] = 0.78; 95% confidence interval [CI]: [0.62, 1.00]; P = 0.05). There was also significant difference in positive resection margin (Relative Risk [RR] = 0.13; 95%CI: [0.09, 0.20]; P < 0.00001) between the two treatment strategies.
Conclusion: The pooled results of this study indicated that surgical treatment had better OS than endoscopic treatment for T1b EC. Furthermore, endoscopic treatment also had significantly higher risk of margin positivity than surgical treatment for T1b EC.
European Journal of Surgical Oncology , résumé 2025